Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (131-140 of 259) with videos related to

Pageof 26
Sort By:
Journal of the National Cancer Institute|August 5, 2020
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine TherapyMaria Alice Franzoi, Daniel Eiger, Lieveke Ameye, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trialChristian F Singer, Franz Koenig, Stephanie Kacerovsky-Strobl, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2017
Recurrence dynamics of breast cancer according to baseline body mass indexElia Biganzoli, Christine Desmedt, Marco Fornili, et al.
Journal of the National Cancer Institute|November 1, 2017
Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor StatusMatteo Lambertini, Niels Kroman, Lieveke Ameye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2009
Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA TrialMitch Dowsett, Marion Procter, Worta McCaskill-Stevens, et al.
Breast Cancer Research : BCR|October 28, 2020
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trialSerena Di Cosimo, Luca Porcu, Dominique Agbor-Tarh, et al.
British Journal of Cancer|June 24, 2020
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathyKamal S Saini, Carlo Lanza, Marco Romano, et al.
JAMA Oncology|April 22, 2016
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA TrialSherene Loi, Urania Dafni, Dimitris Karlis, et al.
Clinical Breast Cancer|January 12, 2020
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast CancerJosé Bines, Marion Procter, Eleonora Restuccia, et al.
Clinical Epidemiology|May 14, 2023
Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative DataHava Izci, Gilles Macq, Tim Tambuyzer, et al.
Pageof 26

Showing results (131-140 of 259) with videos related to

Sort By:
Pageof 26
Journal of the National Cancer Institute|August 5, 2020
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine TherapyMaria Alice Franzoi, Daniel Eiger, Lieveke Ameye, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trialChristian F Singer, Franz Koenig, Stephanie Kacerovsky-Strobl, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2017
Recurrence dynamics of breast cancer according to baseline body mass indexElia Biganzoli, Christine Desmedt, Marco Fornili, et al.
Journal of the National Cancer Institute|November 1, 2017
Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor StatusMatteo Lambertini, Niels Kroman, Lieveke Ameye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2009
Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA TrialMitch Dowsett, Marion Procter, Worta McCaskill-Stevens, et al.
Breast Cancer Research : BCR|October 28, 2020
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trialSerena Di Cosimo, Luca Porcu, Dominique Agbor-Tarh, et al.
British Journal of Cancer|June 24, 2020
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathyKamal S Saini, Carlo Lanza, Marco Romano, et al.
JAMA Oncology|April 22, 2016
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA TrialSherene Loi, Urania Dafni, Dimitris Karlis, et al.
Clinical Breast Cancer|January 12, 2020
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast CancerJosé Bines, Marion Procter, Eleonora Restuccia, et al.
Clinical Epidemiology|May 14, 2023
Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative DataHava Izci, Gilles Macq, Tim Tambuyzer, et al.
Pageof 26